23 patents
Utility
Inducible Caspases and Methods for Use
2 Nov 23
The disclosure provides inducible caspase polypeptides, compositions comprising inducible caspase polypeptides and sequences encoding the same, cells modified to express the polypeptides and compositions of the disclosure, as well as methods of making and methods of using same for adoptive cell therapy.
Eric M. OSTERTAG, Devon Shedlock
Filed: 13 Jun 23
Utility
Compositions and Methods for Directing Proteins to Specific Loci In the Genome
17 Aug 23
Disclosed are compositions and methods for directing proteins to specific loci in the genome and uses thereof.
Eric M. OSTERTAG, Tseten YESHI, Xianghong LI
Filed: 25 Aug 22
Utility
Chimeric Stimulatory Receptors and Methods of Use In T Cell Activation and Differentiation
20 Apr 23
Disclosed are chimeric stimulatory receptors (CSRs), cell compositions comprising CSRs, methods of making and methods of using same for the treatment of a disease or disorder in a subject.
Devon SHEDLOCK, Sumiti JAIN
Filed: 11 Mar 21
Utility
Compositions and Methods for the Treatment of Metabolic Liver Disorders
6 Apr 23
The present disclosure is directed to compositions and methods for the treatment of Metabolic Liver Disorders.
Jingjing JIANG, Julian DOWN, Xianghong LI, Eric M. OSTERTAG
Filed: 4 Mar 21
Utility
ANTI-MUC1 Compositions and Methods of Use
16 Mar 23
Disclosed are antibodies against MUC1, MUC1-CAR compositions and methods for use of these antibodies and compositions to target a MUC1 protein, wherein a cell expressing the MUC1 protein may be targeted and killed by, for instance, a cytotoxic T cell.
Eric M. OSTERTAG, Devon SHEDLOCK
Filed: 18 Dec 20
Utility
Inducible Caspases and Methods for Use
5 Jan 23
The disclosure provides inducible caspase polypeptides, compositions comprising inducible caspase polypeptides and sequences encoding the same, cells modified to express the polypeptides and compositions of the disclosure, as well as methods of making and methods of using same for adoptive cell therapy.
Eric M. OSTERTAG, Devon SHEDLOCK
Filed: 2 Jun 22
Utility
Allogeneic Cell Compositions and Methods of Use
8 Dec 22
Disclosed are chimeric stimulatory receptors (CSRs), cell compositions comprising CSRs, methods of making and methods of using same for the treatment of a disease or disorder in a subject.
Eric M. OSTERTAG, Devon SHEDLOCK
Filed: 5 Sep 19
Utility
Allogeneic Cell Compositions and Methods of Use
24 Nov 22
Disclosed are chimeric stimulatory receptors (CSRs), cell compositions comprising CSRs, methods of making and methods of using same for the treatment of a disease or disorder in a subject.
Eric M. OSTERTAG, Devon SHEDLOCK
Filed: 3 Sep 20
Utility
Nanotransposon Compositions and Methods of Use
10 Feb 22
Disclosed are compositions comprising a first nucleic acid sequence comprising: (a) a first inverted terminal repeat (ITR), (b) a second ITR and (c) an intra-ITR sequence, wherein the intra-ITR sequence comprises a transposon sequence, and a second nucleic acid sequence comprising an inter-ITR sequence, wherein the length of the inter-1TR sequence is between 1 and 600 nucleotides, inclusive of the endpoints.
Eric M. OSTERTAG, Devon SHEDLOCK
Filed: 20 Dec 19
Utility
Vcar Compositions and Methods for Use
13 May 21
Disclosed are VHH chimeric antigen receptors (VCARs), VCAR transposons encoding VCARs of the disclosure, cells modified to express VCARs of the disclosure, as well as methods of making and methods of using the same for adoptive cell therapy.
Eric M. OSTERTAG, Devon SHEDLOCK
Filed: 20 Dec 18
Utility
Compositions and Methods for Chimeric Ligand Receptor (Clr)-mediated Conditional Gene Expression
6 May 21
Disclosed are composition comprising (a) an inducible transgene construct, comprising a sequence encoding an inducible promoter and a sequence encoding a transgene, and (b) a receptor construct, comprising a sequence encoding a constitutive promoter and a sequence encoding an exogenous receptor, wherein, upon integration of the construct of (a) and the construct of (b) into a genomic sequence of a cell, the exogenous reporter is expressed, and wherein the exogenous reporter, upon binding a ligand, transduces an intracellular signal that targets the inducible promoter of (a) to modify gene expression.
Eric M. OSTERTAG, Devon SHEDLOCK
Filed: 10 Sep 18
Utility
Transposon System and Methods of Use
22 Apr 21
Disclosed are methods for the ex-vivo genetic modification of an immune cell comprising delivering to the immune cell, (a) a nucleic acid or amino acid sequence comprising a sequence encoding a transposase enzyme and (b) a recombinant and non-naturally occurring DNA sequence comprising a DNA sequence encoding a transposon.
Devon SHEDLOCK, David HERMANSON, Eric OSTERTAG, Maximilian RICHTER, Stacey Ann CRANERT
Filed: 31 Aug 18
Utility
Site-specific Enzymes and Methods of Use
4 Mar 21
The present invention provides polypeptides related t Ralstonia proteins, nucleic acids encoding the same, compositions comprising the same, kits comprising the same, non-human transgenic animals comprising the same, and methods of using the same.
Eric M. OSTERTAG, Tseten YESHI
Filed: 16 Nov 20
Utility
Compositions and Methods for Inducing Nanoparticle-mediated Microvascular Embolization for Tumors
28 Oct 20
Nanoparticle mediated microvascular embolization (NME) of tumor tissue may occur after systemic administration of PEM, leading to widespread shutdown of vascular flow, hemorrhage, and necrosis.
P. Peter GHOROGHCHIAN
Filed: 9 Jul 20
Utility
Site-specific Enzymes and Methods of Use
24 Jun 20
The present invention provides polypeptides related to Ralstonia proteins, nucleic acids encoding the same, compositions comprising the same, kits comprising the same, non-human transgenic animals comprising the same, and methods of using the same.
Eric M. Ostertag, Tseten Yeshi
Filed: 21 Jul 19
Utility
Compositions and Methods for Inducing Nanoparticle-mediated Microvascular Embolization of Tumors
6 May 20
Nanoparticle mediated microvascular embolization (NME) of tumor tissue may occur after systemic administration of PEM as a result of the nitric oxide sequestration by PEM.
P. Peter GHOROGHCHIAN
Filed: 5 Nov 19
Utility
Modified Stem Cell Memory T Cells, Methods of Making and Methods of Using Same
6 May 20
The disclosure provides a method of producing modified stem memory T cells (e.g.
Eric M. OSTERTAG, Devon SHEDLOCK
Filed: 28 Oct 19
Utility
Hyperactive Piggybac Transposases
18 Mar 20
The present invention provides PiggyBac transposase proteins, nucleic acids encoding the same, compositions comprising the same, kits comprising the same, non-human transgenic animals comprising the same, and methods of using the same.
Eric M. OSTERTAG, Blair MADISON
Filed: 18 Mar 19
Utility
Compositions and Methods for Selective Elimination and Replacement of Hematopoietic Stem Cells
11 Mar 20
Disclosed are methods of eliminating at least on target cell in a subject, comprising administering to the subject an effective amount of a composition comprising a plurality of immune cells, wherein each immune cell of the plurality expresses one or more chimeric ligand receptor(s) (CLR(s)) that each specifically bind to a target ligand on the at least one target cell, wherein specifically binding of the one or more CLR(s) to the target activates the immune cell, and wherein the activated immune cell induces death of the target cell.
Eric M. OSTERTAG, Devon SHEDLOCK, Julian David DOWN
Filed: 12 Mar 18
Utility
CorrectedTransposon System and Methods of Use
26 Feb 20
Disclosed are methods for the ex-vivo genetic modification of an immune cell comprising delivering to the immune cell, (a) a nucleic acid or amino acid sequence comprising a sequence encoding a transposase enzyme and (b) a recombinant and non-naturally occurring DNA sequence comprising a DNA sequence encoding a transposon.
Devon SHEDLOCK, David HERMANSON, Eric OSTERTAG
Filed: 19 Dec 17